Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    TopAbstracts in Diabetes 11/24/2009 - (DGNews)
    TopAbstracts in Diabetes 11/17/2009 - (DGNews)
    Darbepoetin Alfa Risky for Type 2 Diabetics With Kidney Disease: Presented at AHA - (DGDispatch)
    Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial - (BMJ)
    Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials - (BMJ)

    News archive

     Recent webcasts/CME - Diabetes
      Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Diabetes and the Heart: Cardiometabolic Screening and Hospital Care
      Diabetes and the Heart: Diabetes and Glycemic Control - Cardiovascular
      Diabetes and the Heart: Cardiac Care for the Patient with Diabetes: Clinical Horizons
      Increased Cardiovascular Disease Risk in Type 2 Diabetes: Pathophysiology

      Webcasts/CME archive

       Recent cases - Diabetes
        Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Alogliptin Alone and With Add-On, Reduces Hb A1C in Phase 3 Trials

        SAN FRANCISCO -- June 10, 2008 -- Results from 5 pivotal phase 3 studies of alogliptin were announced at the American Diabetes Association (ADA) 68th Scientific Session. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4, is currently under investigation as an oral treatment for type 2 diabetes. Alogliptin administered once daily demonstrated statistically significant reductions in haemoglobin (Hb) A1C versus placebo as a monotherapy and as an add-on therapy with the major classes of type 2 diabetes medications: metformin, thiazolidinediones, insulin, and sulfonylureas.

        Phase 3 studies were conducted in over 2,000 patients in 220 centres worldwide. All 5 phase 3 studies were randomised, double-blind, placebo-controlled studies, designed to assess the efficacy and safety of alogliptin alone, with metformin add-ons, and with sulfonylurea add-ons. The primary endpoint was change from baseline in Hb A1C at week 26 in the intent-to-treat population. Alogliptin was studied at 12.5 mg and 25 mg, once daily, in all studies.

        In all studies, except for the insulin add-on, mean baseline Hb A1C was between 7.9% and 8.1%, and mean duration of type 2 diabetes was between 6 to 8 years. In the insulin add-on, mean baseline Hb A1C was 9.3% and mean duration of type 2 diabetes was 13 years. The mean age of patients in all studies was between 53 and 57 years.

        In all 5 studies, the mean change from baseline Hb A1C levels were significantly greater for both 12.5 mg and 25 mg alogliptin doses versus placebo at the study's end. A greater percentage of patients achieved Hb A1C levels of less than or equal to 7% at both 12.5 mg and 25 mg alogliptin doses versus placebo, in the alogliptin monotherapy, then the metformin add-on studies, and finally, sulfonylurea add-on studies. The mean changes from baseline Hb A1C levels were similar regardless of age, body mass index (BMI), or ethnicity.

        Alogliptin was well-tolerated at all doses and in combination with other type 2 diabetes medications. Common adverse events were similar across groups in each study.

        "Almost half the patients with type 2 diabetes are not at the ADA recommended Hb A1C goal of less than 7%, so it's important to have new treatment options that are both effective and well tolerated to potentially address the large number of patients who aren't adequately controlled," said Richard Pratley, MD, Diabetes & Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont. "These clinical data show that alogliptin effectively reduces blood sugar in patients, alone or when used in combination with existing oral antidiabetic treatments as well as insulin, increasing the range of treatment options for patients."

        SOURCE: Takeda Pharmaceuticals North America



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send